Veloxis Pharmaceuticals Announces Dosing of the First Patient by Partner Xenikos in the Global Phase III Study Evaluating T-Guard^® in Patients with Steroid-Refractory Acute Graft-versus-Host Disease (SR-aGVHD)

Veloxis Pharmaceuticals announced dosing of the first patient by its partner, Xenikos, in a Phase III clinical study designed to evaluate T-Guard® versus ruxolitinib for the treatment of patients with Grade III or IV SR-aGVHD following allogeneic hematopoietic stem cell transplant.